Louis Barrows

Prof. Dr. Louis Barrows

Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, 30 S. 2000 E., Salt Lake City, UT 94112-5820, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2004 in Natural Product Reports
Verified
Journal Article
Closed access
PDF file
KMKathryn M. Marshall
Kathryn M. Marshall
LBLouis Barrows
Louis Barrows
Covering: 1983–2003 This review consolidates biological activity data reported for pyridoacridine 1 molecules in the literature from 1983–2003 into several tables with brief discussions of assays used and results obtained. This review summarizes recent progress in structure activity relationships for analogues of amphimedine 2 and ascididemin 3 classes of pyridoacridines and correlates reported molecular mechanisms of action with biological activities.

7 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
RPRachanida Praparatana
Rachanida Praparatana
PMPattaravan Maliyam
Pattaravan Maliyam
LBLouis Barrows
Louis Barrows
PPPanupong Puttarak
Panupong Puttarak
Bioactive compounds from medicinal plants are good alternative treatments for T2DM. They are also sources of lead molecules that could lead to new drug discoveries. In this study, Bauhinia strychnifolia Craib. stem, a traditional Thai medicinal plant for detoxification, was extracted into five fractions, including crude extract, BsH, BsD, BsE, and BsW, by ethanolic maceration and sequential partition with hexane, dichloromethane, ethyl acetate, and water, respectively. Among these fractions, BsE contained the highest amounts of phenolics (620.67 mg GAE/g extract) and flavonoids (131.35 mg QE/g extract). BsE exhibited the maximum inhibitory activity against α-glucosidase (IC50 1.51 ± 0.01 µg/mL) and DPP-IV (IC50 2.62 ± 0.03 µg/mL), as well as dominantly promoting glucose uptake on 3T3-L1 adipocytes. Furthermore, the four compounds isolated from the BsE fraction, namely resveratrol, epicatechin, quercetin, and gallic acid, were identified. Quercetin demonstrated the highest inhibitory capacity against α-glucosidase (IC50 6.26 ± 0.36 µM) and DPP-IV (IC50 8.25 µM). In addition, quercetin prominently enhanced the glucose uptake stimulation effect on 3T3-L1 adipocytes. Altogether, we concluded that quercetin was probably the principal bioactive compound of the B. strychnifolia stem for anti-diabetic, and the flavonoid-rich fraction may be sufficiently potent to be an alternative treatment for blood sugar control.

7 January 2014 in Journal of Natural Products
Verified
Journal Article
Closed access
RJRaquel C. Jadulco
Raquel C. Jadulco
CPChristopher D. Pond
Christopher D. Pond
RWRyan M. Van Wagoner
Ryan M. Van Wagoner
MKMichael Koch
Michael Koch
OGOsia G. Gideon
Osia G. Gideon
LBLouis Barrows
Louis Barrows

1 July 2009 in Fitoterapia
Verified
Journal Article
Closed access
TBTim S. Bugni
Tim S. Bugni
CACynthia D. Andjelic
Cynthia D. Andjelic
APAnn R. Pole
Ann R. Pole
PRPrem Rai
Prem Rai
CIChris M. Ireland
Chris M. Ireland
LBLouis Barrows
Louis Barrows

8 October 2008 in Marine Drugs
Verified
Journal Article
Open access
PDF file
CACynthia D. Andjelic
Cynthia D. Andjelic
VPVicente Planelles
Vicente Planelles
LBLouis Barrows
Louis Barrows
Papuamide A is representative of a class of marine derived cyclic depsipeptides, reported to have cytoprotective activity against HIV-1 in vitro. We show here that papuamide A acts as an entry inhibitor, preventing human immunodeficiency virus infection of host cells and that this inhibition is not specific to R5 or X4 tropic virus. This inhibition of viral entry was determined to not be due to papuamide A binding to CD4 or HIV gp120, the two proteins involved in the cell-virus recognition and binding. Furthermore, papuamide A was able to inhibit HIV pseudotype viruses expressing envelope glycoproteins from vesicular stomatitis virus or amphotropic murine leukemia virus indicating the mechanism of viral entry inhibition is not HIV-1 envelope glycoprotein specific. Time delayed addition studies with the pseudotyped viruses show that papuamide A inhibits viral infection only at the initial stage of the viral life cycle. Additionally, pretreatment studies revealed that the virus, and not the cell, is the target of papuamide A’s action. Together, these results suggest a direct virucidal mechanism of HIV-1 inhibition by papuamide A. We also demonstrate here that the other papuamides (B-D) are able to inhibit viral entry indicating that the free amino moiety of 2,3-diaminobutanoic acid residue is not required for the virucidal activity.

31 July 1998 in Mutation Research/DNA Repair
Verified
Journal Article
Closed access
LBLouis Barrows
Louis Barrows
JHJoseph A Holden
Joseph A Holden
MAMelvin Anderson
Melvin Anderson
PDPeter D'Arpa
Peter D'Arpa